PMID- 25488963
OWN - NLM
STAT- MEDLINE
DCOM- 20150316
LR  - 20220602
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 2
DP  - 2015 Jan 10
TI  - Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: 
      results of a randomized phase III trial.
PG  - 172-9
LID - 10.1200/JCO.2013.54.3298 [doi]
AB  - PURPOSE: This open-label phase III trial evaluated efficacy and tolerability of 
      linifanib versus sorafenib in patients with advanced hepatocellular carcinoma 
      (HCC) without prior systemic therapy. PATIENTS AND METHODS: Patients were 
      randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib 400 
      mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest 
      of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), 
      vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (HBV) 
      infection (yes or no). The primary end point of the study was overall survival 
      (OS). Secondary end points were time to progression (TTP) and objective response 
      rate (ORR) per RECIST v1.1. RESULTS: We randomly assigned 1,035 patients (median 
      age, 60 years; Asian, 66.6%; ECOG PS 0, 65.2%; HBV, 49.1%; vascular invasion or 
      extrahepatic spread, 70.1%). Median OS was 9.1 months on the linifanib arm (95% 
      CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95% CI, 8.3 to 11.0; hazard 
      ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification 
      subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median 
      TTP was 5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on 
      the sorafenib arm (95% CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P = 
      .001). Best response rate was 13.0% on the linifanib arm versus 6.9% on the 
      sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs; and AEs leading to 
      discontinuation, dose interruption, and reduction were more frequent with 
      linifanib (all P < .001). CONCLUSION: Linifanib and sorafenib had similar OS in 
      advanced HCC. Predefined superiority and noninferiority OS boundaries were not 
      met for linifanib and the study failed to meet the primary end point. TTP and ORR 
      favored linifanib; safety results favored sorafenib.
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Cainap, Calin
AU  - Cainap C
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt. calincainap@yahoo.co.uk.
FAU - Qin, Shukui
AU  - Qin S
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Huang, Wen-Tsung
AU  - Huang WT
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Chung, Ik Joo
AU  - Chung IJ
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Pan, Hongming
AU  - Pan H
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Cheng, Ying
AU  - Cheng Y
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Kudo, Masatoshi
AU  - Kudo M
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Kang, Yoon-Koo
AU  - Kang YK
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Chen, Pei-Jer
AU  - Chen PJ
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Toh, Han-Chong
AU  - Toh HC
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Gorbunova, Vera
AU  - Gorbunova V
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Eskens, Ferry A L M
AU  - Eskens FA
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Qian, Jiang
AU  - Qian J
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - McKee, Mark D
AU  - McKee MD
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Ricker, Justin L
AU  - Ricker JL
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - Carlson, Dawn M
AU  - Carlson DM
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
FAU - El-Nowiem, Saied
AU  - El-Nowiem S
AD  - Calin Cainap, Institute of Oncology, Cluj-Napoca, Romania; Shukui Qin, Chinese 
      People's Liberation Army Cancer Center, Bayi Hospital, Beijing; Hongming Pan, Sir 
      Run Run Shaw Hospital, Zhejiang University, Hangzhou; Ying Cheng, Tumor Hospital 
      of Jilin Province, Changchun, People's Republic of China; Wen-Tsung Huang, Chi 
      Mei Medical Center, Liouying; Pei-Jer Chen, National Taiwan University Hospital, 
      Taipei, Taiwan, Republic of China; Ik Joo Chung, Chonnam National University, 
      Hwasun Hospital, Hwasun, Jeollonam-do; Yoon-Koo Kang, Asan Medical Center, 
      University of Ulsan, Seoul, Republic of Korea; Masatoshi Kudo, Kinki University, 
      Osaka, Japan; Han-Chong Toh, National Cancer Centre, Singapore, Singapore; Vera 
      Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia; Ferry A.L.M. 
      Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the 
      Netherlands; Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, 
      AbbVie, North Chicago, IL; Saied El-Nowiem, Alexandria University, Alexandria, 
      Egypt.
LA  - eng
SI  - ClinicalTrials.gov/NCT01009593
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141208
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - CO93X137CW (linifanib)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
CIN - J Clin Oncol. 2015 Aug 1;33(22):2486. PMID: 26033815
CIN - J Clin Oncol. 2015 Aug 1;33(22):2484-5. PMID: 26033820
EIN - J Clin Oncol. 2017 Aug 1;35(22):2590. PMID: 28750184
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy/etiology/pathology
MH  - Drug Administration Schedule
MH  - Female
MH  - Hand-Foot Syndrome/etiology
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Indazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/*drug therapy/etiology/pathology
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Odds Ratio
MH  - Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Risk Factors
MH  - Sorafenib
MH  - Treatment Outcome
PMC - PMC4279237
COIS- Authors' disclosures of potential conflicts of interest are found in the article 
      online at www.jco.org. Author contributions are found at the end of this article.
EDAT- 2014/12/10 06:00
MHDA- 2015/03/17 06:00
PMCR- 2016/01/10
CRDT- 2014/12/10 06:00
PHST- 2014/12/10 06:00 [entrez]
PHST- 2014/12/10 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
PHST- 2016/01/10 00:00 [pmc-release]
AID - JCO.2013.54.3298 [pii]
AID - 43928 [pii]
AID - 10.1200/JCO.2013.54.3298 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 
      Dec 8.